Please assess the completion status of the following clinical trial:

Trial Title: CHinese Acute Tissue-Based Imaging Selection for Lysis In Stroke -Tenecteplase

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients presenting with anterior circulation acute ischaemic stroke~2. Time from onset to treatment 4.5h-24h~3. Patient's age is ≥18 years~4. Pre-stroke mRS score of \<= 2~5. Clinically significant acute neurologic deficit~6. Vessel occlusion or severe stenosis ( ICA, MCA-M1/M2, ACA) on computed tomography angiography (CTA)/MRA~7. Multimodal CT/magnetic resonance imaging: perfusion lesion volume (DT \> 3 s) to infarct core volume ratio (rCBF\<30% or diffusion-weighted imaging lesion) \>1.2, absolute difference \>10 ml, and ischemic core volume \<70ml~8. Informed consent was obtained from patients.~Exclusion Criteria:~1. Intracranial hemorrhage or subarachnoid hemorrhage identified by CT or MRI~2. Rapidly improving symptoms (patient with an NIHSS score decrease to \< 4 at randomization)~3. Pre-stroke mRS score of \> 2~4. Contraindication to imaging with CT/magnetic resonance imaging with contrast agents~5. Infarct core \>1/3 middle cerebral artery (MCA) territory~6. Platelet count \< 100x10\^9/L~7. Symptoms were caused by low blood glucose \< 2.7 mmol/l~8. Severe uncontrolled hypertension, i.e. systolic blood pressure \>= 180 mmHg or diastolic blood pressure \>=100 mmHg~9. Current use of warfarin with a prolonged prothrombin time (INR \> 1.7 or prothrombin time \> 15s)~10. Use of low molecular weight heparin within 24 hours~11. Use of non-vitamin K antagonist oral anticoagulants (NOACs) within 48 hours~12. Use of glycoprotein IIb - IIIa inhibitors within 72 hours.~13. Arterial puncture at noncompressible site in previous 7 days~14. Major surgery in previous 14 days which poses risk in the opinion of the investigator~15. Recent gastrointestinal or urinary tract hemorrhage (within previous 21 days)~16. Significant head trauma or prior stroke in previous 3 months~17. History of previous intracranial hemorrhage, intracranial neoplasm, arteriovenous malformation, or aneurysm. Risks were considered by the investigator~18. Hereditary or acquired haemorrhagic diathesis~19. Active internal bleeding~20. Symptoms suggestive or recent acute pancreatitis, active gastrointestinal ulcer~21. Severe liver disease, including liver failure, cirrhosis, portal hypertension and active hepatitis~22. Pregnancy~23. Various dying diseases with life expectancy ≤3 months~24. Other conditions in which doctors believe that participating in this study may be harmful to the patient~25. Patients participated in any observational trial in 30 days~26. Allergic to the test drug and its ingredients

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Low dose tenecteplase (Type: EXPERIMENTAL): None
- High dose tenecteplase (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).